The 2025-2026 Annual Influenza letter (PDF) is available. The letter summarizes the 2025-2026 Advisory Council on Immunization Practices recommendations.
Influenza vaccination is recommended for all persons aged ≥6 months. Influenza vaccines available during the 2025–2026 season are:
- Trivalent inactivated influenza vaccine (IIV3)
- Sanofi Pasteur (Fluzone Trivalent)
- GlaxoSmithKline (Fluarix Trivalent)
- GlaxoSmithKline (FluLaval Trivalent)
- Seqirus (Afluria Trivalent)
- Sanofi Pasteur (Fluzone High-Dose Trivalent: HD-IIV3)
- Trivalent cell-culture based influenza vaccine (ccIIV3): Seqirus (Flucelvax Trivalent)
- Live-attenuated influenza vaccine, trivalent (LAIV3): AstraZeneca (FluMist Trivalent)
- Adjuvanted inactivated influenza vaccine, trivalent (aIIV3): Sequirus (Fluad Trivalent)
- Recombinant hemagglutinin (HA) influenza vaccine (RIV3): Sanofi Pasteur (FluBlok Trivalent)
Not all influenza vaccines are uniformly available in any given practice setting or geographic locality. ACIP recommends that adults aged ≥65 years preferentially receive an enhanced influenza vaccine (EIV) to improve their immunity. Any one of the following enhanced vaccines are preferred for this group: trivalent high-dose inactivated influenza vaccine – Fluzone HighDose (HD-IIV3), FluBlok (RIV3), or Fluad (aIIV3). If none of these three vaccines are available at an opportunity for vaccine administration, then any other age-appropriate influenza vaccine can be used. Vaccination should not be delayed to obtain a specific product when an dhs.wisconsin.gov appropriate one is already available. To avoid missed opportunities for vaccination, providers should offer vaccination during routine health care visits and hospitalizations when vaccine is available. Respiratory vaccine season is also a great time to check vaccine records or the Wisconsin Immunization Registry to see what other immunizations for which an individual may be eligible.